BAY 949392

Drug Profile

BAY 949392

Alternative Names: 18F-FSPG; BAY94-9392; FSPG

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; National Cancer Institute (USA); Piramal Enterprises; Stanford University
  • Class Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cancer
  • No development reported Brain cancer; Inflammation

Most Recent Events

  • 05 Jun 2018 Asan Foundation plans a phase II trial for Inflammatory bowel disease in South Korea , (NCT03546868)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Brain-cancer(Diagnosis) in USA (IV)
  • 11 Sep 2017 Vanderbilt-Ingram Cancer Center and National Cancer Institute plan a phase I trial for Colorectal cancer (Diagnosis, Late-stage disease, Metastatic disease) in USA (NCT03275974)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top